Tier 2 — strong

Improving quercetin bioavailability: A systematic review and meta-analysis of human intervention studies

Lu Liu, Elizabeth Barber, Nicole J Kellow, Gary Williamson
Food chemistry 2025 477:143630

Bibliography

PubMed
PMID 40037045
DOI
10.1016/j.foodchem.2025.143630
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
Reported disclosure: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Gary Williamson reports a relationship with Access Business Group LLC West Coast Office that includes: consulting or advisory and funding grants. Gary Williamson reports a relationship with The Product Makers, Australia that includes: funding grants. Other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Study snapshot

DesignSystematic review and meta-analysis of human absorption interventions
ModelHuman evidence synthesis
Sample31 human intervention studies
InterventionQuercetin glycosides, delivery systems, and food-matrix strategies
DurationSearches through July 2024
EndpointsExposure and pharmacokinetics

What the study showed, in plain terms

Published in 2025, this source examined forms, absorption and food sources. Its evidence base was 31 human intervention studies. It evaluated Quercetin glycosides, delivery systems, and food-matrix strategies across Searches through July 2024.

Chemical form, formulation, fat, and fiber affected measured quercetin exposure, sometimes substantially.

Comparisons involved small heterogeneous studies and different analytes. Large exposure ratios do not establish proportional clinical benefits or equivalence between commercial products.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin Forms: Dihydrate, Phytosome, Liposomal and Glycosides. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Chemical form, formulation, fat, and fiber affected measured quercetin exposure, sometimes substantially.
  • The recorded outcome domains were Exposure and pharmacokinetics.

What this study can and cannot tell us

  • Comparisons involved small heterogeneous studies and different analytes. Large exposure ratios do not establish proportional clinical benefits or equivalence between commercial products.
  • The conclusions inherit the limitations of the underlying studies. A narrative interpretation or guideline recommendation is not a new randomized treatment comparison.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Citation network

Articles citing this research paper

4 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology